Skip to main content
OpenTrials
Completed

NCT Number: NCT05273489

Chemotherapy and Tumor Clearance in Hepatic Resections for Colorectal Liver Metastases.

Retrospective analysis of a prospectively collected database of 170 patients between 2004 and 2020, who underwent liver resections for CRLM (colorectal liver metastases) at The Queen Elizabeth Hospital trying to determine rates and patterns of recurrence following liver resections for CRLM and concurrently, characterise clinical, pathological and treatment-related factors that could function as predictors of recurrence or survival, particularly neoadjuvant chemotherapy and tumour clearance.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Colorectal Cancer Metastatic Liver Metastases

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

About this study

This is a descriptive, observational study with retrospective analysis of a prospectively collated database. This database included all patients who underwent curative hepatic resections for CRLM (colorectal liver metastases) at The Queen Elizabeth Hospital (Adelaide, Australia) between December 2004 and October 2020.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patients who underwent a liver resection for CRLM at The Queen Elizabeth Hospital between December 2004 to September 2020

Exclusion criteria

  • Patients whose procedures were abandoned due to unresectable tumour burden

Treatment and study plan

Hepatectomy

Procedure

Neoadjuvant treatment

Other names: Chemotherapy

Primary outcomes

  1. Recurrence

    Time frame: From surgery to recurrence, up to 16 years

    Recurrence rate

  2. Survival

    Time frame: From surgery to death or end of the study, up to 16 years

    up to16 years

Secondary outcomes

  1. Resection margins

    Time frame: From surgery to death or end of the study, up to 16 years

    Resection margins of the liver resection

  2. Neoadjuvant Chemotherapy

    Time frame: From surgery to death or end of the study, up to 16 years

    Neoadjuvant Chemotherapy (yes or not)

Sponsors and collaborators

Lead sponsor

Hospital Maciel

Other

Collaborators

  • University of Adelaide

Registry information

Official study title

Effect of Chemotherapy and Tumor Clearance in Hepatic Resections for Colorectal Liver Metastases. A Single-centre Cohort Study

Important dates

Study start
2004
Primary completion
2020
Study completion
2021
First posted
Mar 10, 2022
Registry last updated
Mar 10, 2022

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.